TScan Therapeutics Welcomes Stephen Camiolo to the Team
WALTHAM, Mass. – TScan Therapeutics, Inc. (Nasdaq: TCRX), a pioneering name in biotechnology focusing on T cell receptor (TCR)-engineered T cell (TCR-T) therapies, has exciting news: they have brought on board Stephen Camiolo as the new Senior Vice President of Market Access. Stephen arrives with over 25 years of comprehensive experience in market access, pricing strategies, and commercial leadership, previously making significant contributions in the pharmaceutical and biotechnology sectors.
Experienced Leadership for Strategic Growth
Gavin MacBeath, Ph.D., the Chief Executive Officer of TScan, expressed enthusiasm about Stephen’s appointment. He noted that Stephen's exceptional track record includes successfully leading over 16 product launches across various disease areas, including important cell therapies. This background positions him as a vital asset for TScan as they gear up for a pivotal trial of their novel TCR-T therapy, TSC-101, targeting local disease management in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS).
Excitement for Transformative Opportunities
Stephen himself is keenly looking forward to contributing to TScan at such an exciting juncture. He acknowledged the remarkable strides the company has made within its clinical pipeline over the past year. With several key milestones approaching, Stephen aims to leverage his extensive experience in cell therapy to propel TScan’s mission of delivering groundbreaking TCR-T therapies to patients battling various hematologic and solid tumor cancers.
Camiolo's Rich Background in Cellular Therapy
Before joining TScan, Stephen served as Vice President of National Cell Therapy Account Teams at Iovance Biotherapeutics, where he played an integral role in the strategic launch of AMTAGVI, a pioneering cell therapy aimed at solid tumor cancers. His previous roles include overseeing market access operations and pricing strategies at Iovance, and leading global market access and reimbursement at CRISPR Therapeutics AG for several allogeneic CAR-T initiatives.
Broad Experience Across the Industry
Stephen has an impressive history that encompasses significant positions at Gilead Sciences, where he worked on market access strategies, and at Kite Pharma, where he managed key accounts strategy post-acquisition. Starting his career at Novartis Pharmaceuticals, Stephen holds a B.S.N. from Spalding University, underlining his solid foundation in both clinical and commercial landscapes.
TScan's Commitment to Cancer Therapy Innovation
TScan Therapeutics is not just enhancing its leadership but is also focused on advancing its clinical programs. The company’s TCR-T therapy candidates play a critical role in treating hematologic malignancies, particularly in preventing relapse after allogeneic hematopoietic cell transplantation. TScan's innovative ImmunoBank continues to grow, ensuring that a diverse range of therapeutic TCR options is available, providing customized treatment approaches for various cancers as part of their PLEXI-T study.
Looking Ahead
The upcoming endeavors mark a transformative phase for TScan as they prepare for significant clinical developments. As they work towards achieving their objectives, Stephen Camiolo’s leadership will be central in navigating these complexities, capitalizing on market access strategies to ensure that patients receive timely and effective treatments.
Frequently Asked Questions
Who is Stephen Camiolo?
Stephen Camiolo is the newly appointed Senior Vice President of Market Access at TScan Therapeutics, with over 25 years of experience in the field.
What is TScan Therapeutics focused on?
TScan Therapeutics specializes in the development of T cell receptor-engineered T cell therapies for cancer treatment.
What will Stephen be responsible for at TScan?
Stephen will oversee market access strategies, reimbursement, and pricing as TScan prepares for significant clinical milestones.
What are TScan’s main clinical programs?
TScan's main clinical programs include TSC-101 for preventing relapse in hematologic malignancies and the PLEXI-T program for solid tumors.
How does TScan plan to support cancer patients?
TScan aims to deliver innovative TCR-T therapies targeting various cancers, ensuring that patients have access to advanced treatment options through their clinical programs.
